axicabtagene ciloleucel for Follicular Lymphoma
This trial will enroll 160 adults with relapsed or refractory non-Hodgkin's lymphoma. Subjects will receive axicabtagene ciloleucel, an experimental product made from the subject's own genetically-modified white blood cells. The goal is to determine if the product is safe and effective.
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Slow-Growing Non-Hodgkin's Lymphoma
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
How many venues is this experiment currently taking place in?
"Currently, 17 medical facilities are hosting this clinical trial. In addition to Seattle, Gilbert and Miami, there are 14 additional sites. To best accommodate your needs, it is important that you choose the closest clinic when deciding whether or not to join the study."
Are there any openings remaining for participants in this trial?
"Clinicaltrials.gov indicates that, as of this moment, the trial is not currently accepting applications. This study was initially posted on June 20th 2017 and most recently updated November 22nd 2022; however, 2644 other medical studies are still accepting participants at present."
Could you elucidate what other tests have been undertaken with axicabtagene ciloleucel?
"Currently, 894 active clinical trials are being conducted in order to further research axicabtagene ciloleucel. Of those studies, 161 have reached Phase 3 status. Furthermore, 28479 locations across the globe are researching this treatment with the majority of them located in Philadelphia, Pennsylvania."
What precautions should be taken when using axicabtagene ciloleucel?
"As axicabtagene ciloleucel is only in Phase 2, the limited data available suggests it has a relatively high safety profile. Thus, our team at Power rated it as a level 2 on their scale of 1 to 3."
How many individuals are currently enrolled in this experiment?
"At the present time, this investigation is not actively recruiting participants. It was initially posted on June 20th 2017 and last updated November 22nd 2022. Other studies in related fields include 1,750 trials for those with lymphoma and 894 involving axicabtagene ciloleucel that are currently looking for patients to take part."